The Fourth Affiliated Hospital, Zhejiang University School of Medicine
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Lunfei
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed
3
336
Canada, RoW
Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2
Reistone Biopharma Company Limited
Atopic Dermatitis
08/22
05/23
NCT06173284: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Recruiting
3
510
RoW
611, Matching placebo
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Dermatitis, Atopic
09/25
05/26
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
430
RoW
Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid
Eli Lilly and Company
Atopic Dermatitis
12/25
11/26
HDM3014-301, NCT06648772: Efficacy and Safety of Roflumilast Cream 0.3% in Subjects with Plaque Psoriasis: a Phase 3 Study

Recruiting
3
189
RoW
Roflumilast Cream 0.3%, Zoryve, Vehicle cream
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Plaque Psoriasis
06/25
07/25
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis

Recruiting
3
552
RoW
ICP-332 Tablets, ICP-332 Placebo Tablets
Beijing InnoCare Pharma Tech Co., Ltd.
Atopic Dermatitis
11/26
12/26
SSGJ-611-AD-II-01, NCT05544591: Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Completed
2
93
RoW
611 Q2W, 611 Q4W, Matching placebo, placebo
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Dermatitis, Atopic
07/23
09/23
AtDvance, NCT06447506: Long-Term Study () to Evaluate GSK1070806 in Atopic Dermatitis.

Recruiting
2
159
Europe, Canada, Japan, US, RoW
GSK1070806
GlaxoSmithKline
Dermatitis, Atopic
11/29
11/29
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Recruiting
2
199
Europe, Canada, Japan, US, RoW
GSK1070806, Placebo
GlaxoSmithKline
Dermatitis, Atopic
10/25
01/26

Download Options